| Symbol | MLTX |
|---|---|
| Name | MOONLAKE IMMUNOTHERAPEUTICS |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | DORFSTRASSE 29, ZUG, 6300, Switzerland |
| Telephone | +41 41 - 5108022 |
| Fax | — |
| — | |
| Website | https://www.moonlaketx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001821586 |
| Description | MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. Additional info from NASDAQ: |
2026-05-15 14:27
New Form SCHEDULE 13G/A - MoonLake Immunotherapeutics <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001172661-26-002221 <b>Size:</b> 9 KB
Read more
2026-05-13 20:10
Bodenstedt Matthias 🔴 sold 13.7K shares of MoonLake Immunotherapeutics (MLTX) at $20.02 Transaction Date: May 11, 2026 | Filing ID: 055799
Read more
2026-05-11 11:09
(30% Negative) MOONLAKE IMMUNOTHERAPEUTICS (MLTX) Reports Q2 2026 Financial Results
Read more
2026-05-10 13:00
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
Read more
2026-04-21 17:32
New Form DEFA14A - MoonLake Immunotherapeutics <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001140361-26-015917 <b>Size:</b> 3 MB
Read more
2026-04-21 17:32
New Form ARS - MoonLake Immunotherapeutics <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001140361-26-015918 <b>Size:</b> 2 MB
Read more
2026-04-21 17:31
New Form DEF 14A - MoonLake Immunotherapeutics <b>Filed:</b> 2026-04-21 <b>AccNo:</b> 0001140361-26-015916 <b>Size:</b> 6 MB
Read more
2026-04-16 20:10
Bodenstedt Matthias 🔴 sold 2.4K shares of MoonLake Immunotherapeutics (MLTX) at $19.56 Transaction Date: Apr 14, 2026 | Filing ID: 044642
Read more
2026-04-14 21:55
Director Santos da Silva Jorge 🔴 sold 150.0K shares of MoonLake Immunotherapeutics (MLTX) at $18.41 ($2.8M) Transaction Date: Apr 10, 2026 | Filing ID: 043647
Read more
2026-04-10 22:06
Bodenstedt Matthias 🔴 sold 87.8K shares of MoonLake Immunotherapeutics (MLTX) at $19.51 ($1.7M) Transaction Date: Apr 09, 2026 | Filing ID: 042629
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07223138 | A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcuta… | Phase3 | Arthritis, Psoriatic | Enrolling_By_Invitation | 2025-11-13 | 2028-02-04 | ClinicalTrials.gov |
| NCT07007637 | A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcuta… | Phase3 | Hidradenitis Suppurativa | Enrolling_By_Invitation | 2025-06-27 | 2028-06-13 | ClinicalTrials.gov |
| NCT06994936 | An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence o… | Phase1 | Relative Bioequivalence | Completed | 2025-06-05 | 2025-11-01 | ClinicalTrials.gov |
| NCT06768671 | An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subc… | Phase3 | Hidradenitis Suppurativa | Active_Not_Recruiting | 2024-12-30 | 2026-09-28 | ClinicalTrials.gov |
| NCT06641089 | Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-… | Phase3 | Arthritis, Psoriatic | Recruiting | 2024-10-15 | 2027-01-15 | ClinicalTrials.gov |
| NCT06641076 | Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to … | Phase3 | Arthritis, Psoriatic | Active_Not_Recruiting | 2024-10-15 | 2027-02-04 | ClinicalTrials.gov |
| NCT06411899 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compare… | Phase3 | Hidradenitis Suppurativa | Active_Not_Recruiting | 2024-05-15 | 2026-06-17 | ClinicalTrials.gov |
| NCT06411379 | Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared … | Phase3 | Hidradenitis Suppurativa | Active_Not_Recruiting | 2024-05-14 | 2026-06-17 | ClinicalTrials.gov |
| NCT05640245 | Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic A… | Phase2 | Arthritis, Psoriatic | Completed | 2022-12-13 | 2024-01-15 | ClinicalTrials.gov |
| NCT05322473 | Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to… | Phase2 | Hidradenitis Suppurativa | Completed | 2022-04-25 | 2023-08-30 | ClinicalTrials.gov |
Total clinical trials: 10
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ENROLLING_BY_INVITATION | NCT07223138 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ENROLLING_BY_INVITATION | NCT07223138 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ENROLLING_BY_INVITATION | NCT07223138 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ENROLLING_BY_INVITATION | NCT07223138 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ENROLLING_BY_INVITATION | NCT07223138 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ENROLLING_BY_INVITATION | NCT07223138 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ENROLLING_BY_INVITATION | NCT07223138 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ENROLLING_BY_INVITATION | NCT07223138 |
| Sonelokimab | Other | Phase PHASE3 | Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | NCT06768671 |
| Sonelokimab | Other | Phase PHASE3 | Hidradenitis Suppurativa | ENROLLING_BY_INVITATION | NCT07007637 |
| Sonelokimab | Other | Phase PHASE3 | Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | NCT06768671 |
| Sonelokimab | Other | Phase PHASE3 | Hidradenitis Suppurativa | ENROLLING_BY_INVITATION | NCT07007637 |
| Sonelokimab | Other | Phase PHASE3 | Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | NCT06768671 |
| Sonelokimab | Other | Phase PHASE3 | Hidradenitis Suppurativa | ENROLLING_BY_INVITATION | NCT07007637 |
| Sonelokimab | Other | Phase PHASE3 | Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | NCT06768671 |
| Sonelokimab | Other | Phase PHASE3 | Hidradenitis Suppurativa | ENROLLING_BY_INVITATION | NCT07007637 |
| Sonelokimab | Other | Phase PHASE3 | Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | NCT06768671 |
| Sonelokimab | Other | Phase PHASE3 | Hidradenitis Suppurativa | ENROLLING_BY_INVITATION | NCT07007637 |
| Sonelokimab | Other | Phase PHASE3 | Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | NCT06768671 |
| Sonelokimab | Other | Phase PHASE3 | Hidradenitis Suppurativa | ENROLLING_BY_INVITATION | NCT07007637 |
| Sonelokimab | Other | Phase PHASE3 | Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | NCT06768671 |
| Sonelokimab | Other | Phase PHASE3 | Hidradenitis Suppurativa | ENROLLING_BY_INVITATION | NCT07007637 |
| Sonelokimab | Other | Phase PHASE3 | Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | NCT06768671 |
| Sonelokimab | Other | Phase PHASE3 | Hidradenitis Suppurativa | ENROLLING_BY_INVITATION | NCT07007637 |
| Sonelokimab | Other | Phase PHASE3 | Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | NCT06768671 |
| Sonelokimab | Other | Phase PHASE3 | Hidradenitis Suppurativa | ENROLLING_BY_INVITATION | NCT07007637 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT05322473 |
| Adalimumab | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT05322473 |
| Sonelokimab (M1095) | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT05322473 |
| Adalimumab | Other | Phase PHASE2 | Arthritis, Psoriatic | COMPLETED | NCT05640245 |
| Placebo | Other | Phase PHASE2 | Arthritis, Psoriatic | COMPLETED | NCT05640245 |
| Sonelokimab | Other | Phase PHASE2 | Arthritis, Psoriatic | COMPLETED | NCT05640245 |
| Placebo | Other | Phase PHASE3 | Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | NCT06411899 |
| Sonelokimab | Other | Phase PHASE3 | Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | NCT06411899 |
| Placebo | Other | Phase PHASE3 | Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | NCT06411379 |
| Sonelokimab | Other | Phase PHASE3 | Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | NCT06411379 |
| Sonelokimab | Other | Phase PHASE1 | Relative Bioequivalence | COMPLETED | NCT06994936 |
| Sonelokimab | Other | Phase PHASE3 | Hidradenitis Suppurativa | RECRUITING | NCT06768671 |
| Sonelokimab | Other | Phase PHASE3 | Hidradenitis Suppurativa | ENROLLING_BY_INVITATION | NCT07007637 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ENROLLING_BY_INVITATION | NCT07223138 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ACTIVE_NOT_RECRUITING | NCT06641076 |
| Risankizumab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Placebo | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | RECRUITING | NCT06641089 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ENROLLING_BY_INVITATION | NCT07223138 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ENROLLING_BY_INVITATION | NCT07223138 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ENROLLING_BY_INVITATION | NCT07223138 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ENROLLING_BY_INVITATION | NCT07223138 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ENROLLING_BY_INVITATION | NCT07223138 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ENROLLING_BY_INVITATION | NCT07223138 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ENROLLING_BY_INVITATION | NCT07223138 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ENROLLING_BY_INVITATION | NCT07223138 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ENROLLING_BY_INVITATION | NCT07223138 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ENROLLING_BY_INVITATION | NCT07223138 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ENROLLING_BY_INVITATION | NCT07223138 |
| Sonelokimab | Other | Phase PHASE3 | Arthritis, Psoriatic | ENROLLING_BY_INVITATION | NCT07223138 |
Total products: 185